We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Industry Applauds FDA Electronic Submission Gateway Initiative

Industry Applauds FDA Electronic Submission Gateway Initiative

August 15, 2006

Regulated companies that had been nervous about sending esubmissions to the FDA should applaud the agency's new tool to help it receive and process electronic drug, biologic and device applications in an effort to keep up with industry's use of internet submissions, InfoStrength President Rita Geiger told PIR last week.

The agency announced in an Aug. 8 Federal Register notice the availability of its Electronic Submissions Gateway (ESG) to help the FDA handle a growing number of new drug, investigational new drug and biologic license applications and investigational device exemptions submitted electronically. "The increasing number of electronic submissions highlights a critical need to automate and standardize the receipt of these submissions and their delivery to the appropriate centers," the notice said.

"This is a good thing and important step forward because it helps companies feel secure about sending intellectual property over the internet to the FDA," Geiger said.

While noting that it was several years in the making, OfniSystems President Ty Mew also praised the ESG. "It should encourage more companies to migrate to esystems," he told PIR.

The FDA's action addresses the two largest reservations felt most acutely by mid- and small-sized companies: Security fears and new infrastructure costs.

"This allows smaller companies in particular to know they don't have to worry about buying expensive new document management solutions in order to send esubmissions to the FDA," Geiger said. She applauded the agency for recognizing and addressing the fact that many small companies would avoid esubmissions because of cost fears. "Companies won't have to worry about this issue now," she said.

The ESG automates the receipt, acknowledgement to the applicant or sponsor, routing and notification to a receiving center of esubmissions. The use of the ESG is voluntary, the agency said.

The FDA's ESG offers two secure communication options for applicants that already have established gateway systems:

Simple Mail Transfer Protocol (SMTP) with secure/multipurpose internet mail extensions (S/MIME) to provide secure email communication; and Another option that supports faster information exchange and uses hypertext transfer protocol secure (HTTPS) to provide real-time internet communication.

WebTrader is a free applet that can be downloaded from the FDA and requires only a standard security certificate to provide applicants with a secure internet connection to the agency. "The WebTrader addresses the need to expand participation in electronic submissions without costly expenditures for infrastructure upgrades and gateway systems," the agency said in the Federal Register notice.

"All of this will make the industry feel much better about sending esubmissions" to the FDA, Geiger said. In particular, she said the WebTrader option is an effective way to encourage esubmissions because it means that companies will now only need a laptop and a Web connection to send secure esubmissions to the agency. "This is super, it is really helpful for those companies," she stressed.

To use the FDA ESG, send an email to the agency at esgprep@fda.gov (mailto:esgprep@fda.gov) to begin the registration process. The email should include your name, phone number and company name. It should also state whether you are using WebTrader, SMTP or HTTPS for submissions.

To view the Federal Register notice go to: www.fda.gov/OHRMS/DOCKETS/98fr/92s-0251-n000002.pdf (http://www.fda.gov/OHRMS/DOCKETS/98fr/92s-0251-n000002.pdf). To get information on the ESG go to: www.fda.gov/esg/ (http://www.fda.gov/esg/). -- Michael Causey

KEYWORDS esubmission FDA

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing